GRCL - Gracell ends IPO quiet period with favorable views from analysts

Gracell Biotechnologies (GRCL) has dropped ~3.0% over the past two-week period. However, the stock has jumped 22.1% today after Wall Street analysts weighed in on the stock with a string of buy ratings as the company’s IPO quiet period ends.Gracell made a debut at Wells Fargo with a recommendation of overweight. PT set to $33, a ~51.3% upside to the previous close.The analyst calls Gracell’s novel CAR-T cell platform as ‘highly differentiated’ with a 'tangible opportunity for two potential best-in-class CAR-T therapeutics.’Gracell Biotechnologies (GRCL) was rated new buy at Jefferies; PT $30, while Piper Sandler initiated coverage with an overweight recommendation. PT set to $40, implying an 83% increase from the last price.The company’s lead asset GC027 has achieved multiple complete responses in relapsed or refractory T cell acute lymphoblastic leukemia in an ongoing investigator-initiated Phase 1 trial in China.Last month, National Medical Products Administration in China signed off Gracell's application to study

For further details see:

Gracell ends IPO quiet period with favorable views from analysts